Advertisement

Clinical Dilemmas in Anticoagulation: Extremes of Weight, Renal Disease, Recent Bleeding, and Surgery

  • Thomas G. DeLougheryEmail author
Chapter

Abstract

Clinical trials of antithrombotic agents enrolled thousands of patients and form the basis of current recommendations for therapy. However, many patients with thrombosis were not adequately represented in clinical trials. These would include patients at extremes of weight, those with renal disease, those with recent bleeding, and those who need surgery. This chapter reviews many challenging clinical situations such as anticoagulation in those with renal disease and restarting anticoagulation after bleeding. Recommendations are made based on the limited data available.

Keywords

Antithrombotic therapy Renal disease Direct oral anticoagulants Pregnancy 

Suggested Reading

  1. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, Majoie CB, Beenen LF, Marquering HA, Vermeulen M, Nederkoorn PJ, de Haan RJ, Roos YB, Investigators PATCH. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387(10038):2605–13.CrossRefGoogle Scholar
  2. Chousou PA, Pugh PJ. Managing anticoagulation in patients receiving implantable cardiac devices. Futur Cardiol. 2018;14(2):151–64.CrossRefGoogle Scholar
  3. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S, POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370(16):1494–503.CrossRefGoogle Scholar
  4. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–33.CrossRefGoogle Scholar
  5. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–85.CrossRefGoogle Scholar
  6. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, Tilea A, Stack AG, Balkrishnan R, Yao X, Noseworthy PA, Shah ND, Saran R, Nallamothu BK. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519–29.CrossRefGoogle Scholar
  7. Zhou Z, Yu J, Carcel C, Delcourt C, Shan J, Lindley RI, Neal B, Anderson CS, Hackett ML. Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open. 2018;8(5):e019672.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Hematology/Medical OncologyKnight Cancer Center, Oregon Health & Sciences UniversityPortlandUSA

Personalised recommendations